Roivant Sciences Files 8-K: Operations & Financial Update
Ticker: ROIV · Form: 8-K · Filed: Apr 2, 2026 · CIK: 0001635088
| Field | Detail |
|---|---|
| Company | Roivant Sciences Ltd. (ROIV) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0000000341740141, $4.3 billion, $109.7 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financials, operations
TL;DR
Roivant Sciences dropped an 8-K on 4/2/26 covering financials and Reg FD stuff.
AI Summary
Roivant Sciences Ltd. filed an 8-K on April 2, 2026, reporting on their Results of Operations and Financial Condition, and providing Regulation FD Disclosures. The filing includes financial statements and exhibits, with the primary document being an iXBRL 8-K.
Why It Matters
This 8-K filing provides crucial updates on Roivant Sciences' financial performance and operational status, offering insights for investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting operational and financial results, not indicating any immediate or significant new risks.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Filer
- 0001635088 (company) — CIK number for Roivant Sciences Ltd.
- 0001140361-26-012885 (filing_id) — SEC Accession Number
- 2026-04-02 (date) — Filing Date and Period of Report
FAQ
What specific items are covered in Roivant Sciences' 8-K filing dated April 2, 2026?
The filing covers Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
What is the SEC accession number for this Roivant Sciences 8-K filing?
The SEC accession number for this filing is 0001140361-26-012885.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 2, 2026, at 07:00:32.
What is the CIK number for Roivant Sciences Ltd.?
The CIK number for Roivant Sciences Ltd. is 0001635088.
What are the business and mailing addresses listed for Roivant Sciences Ltd.?
Both the business and mailing addresses are listed as 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB.
Filing Stats: 789 words · 3 min read · ~3 pages · Grade level 10.2 · Accepted 2026-04-02 07:00:32
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
- $4.3 billion — s as of March 31, 2026 of approximately $4.3 billion. For the three months ended March 31, 2
- $109.7 million — gregate purchase price of approximately $109.7 million (excluding fees and commission). The i
Filing Documents
- ef20069685_8k.htm (8-K) — 32KB
- ef20069685_ex99-1.htm (EX-99.1) — 23KB
- 0001140361-26-012885.txt ( ) — 188KB
- roiv-20260402.xsd (EX-101.SCH) — 4KB
- roiv-20260402_lab.xml (EX-101.LAB) — 21KB
- roiv-20260402_pre.xml (EX-101.PRE) — 16KB
- ef20069685_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition On April 2, 2026, Roivant Sciences Ltd. (the "Company") announced preliminary unaudited consolidated cash, cash equivalents and marketable securities as of March 31, 2026 of approximately $4.3 billion. For the three months ended March 31, 2026, the Company repurchased 3,956,362 common shares for an aggregate purchase price of approximately $109.7 million (excluding fees and commission). The information in this Item 2.02 is unaudited and preliminary and does not present all information necessary for an understanding of the Company's results of operations for the fiscal year ended March 31, 2026. The audit of the Company's financial statements for the fiscal year ended March 31, 2026 is ongoing and could result in changes to the information in this Item 2.02. The information furnished under this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933. The information in this Item 2.02 shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01
Item 7.01. Regulation FD Disclosure On April 2, 2026, the Company issued a press release announcing a new Phase 2b/3 clinical program at Priovant for brepocitinib in lichen planopilaris. The press release also reported the topline results from Immunovant's two Phase 3 clinical studies evaluating batoclimab as an investigational treatment for adults with active, moderate-to-severe thyroid eye disease. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated by reference in this Item 7.01. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release, dated April 2, 2026. 104 Cover Page Interactive Data File (embedded with Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory Dated: April 2, 2026